Alvotech (NASDAQ:ALVO - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $11.91, but opened at $12.49. Alvotech shares last traded at $12.32, with a volume of 8,221 shares trading hands.
Alvotech Trading Up 5.1 %
The business has a 50 day simple moving average of $12.21 and a two-hundred day simple moving average of $12.09. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -6.77 and a beta of -0.15.
Institutional Trading of Alvotech
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Richmond Brothers Inc. acquired a new position in Alvotech during the 2nd quarter worth $170,000. Wolverine Asset Management LLC bought a new position in shares of Alvotech during the third quarter worth about $70,000. Royce & Associates LP grew its stake in Alvotech by 39.4% in the third quarter. Royce & Associates LP now owns 131,000 shares of the company's stock worth $1,559,000 after purchasing an additional 37,000 shares in the last quarter. PointState Capital LP raised its stake in Alvotech by 3.6% during the third quarter. PointState Capital LP now owns 756,553 shares of the company's stock valued at $9,003,000 after buying an additional 26,481 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Alvotech by 11.2% during the 3rd quarter. Geode Capital Management LLC now owns 209,257 shares of the company's stock worth $2,490,000 after buying an additional 21,022 shares during the last quarter.
About Alvotech
(
Get Free Report)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Featured Stories
Before you consider Alvotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alvotech wasn't on the list.
While Alvotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
